Photo Credit: Mohammed Haneefa Nizamudeen

Loss of vimentin expression was associated with metastases and worse survival in patients with endometrial cancer (EC), according to a multicenter cohort study published in BJC Reports. To assess its prognostic value, Marta Hjelmeland and colleagues evaluated vimentin expression in preoperative biopsies from 1,483 patients with EC 14 European hospitals. Vimentin loss was significantly associated with aggressive disease and worse disease-specific survival (aHR, 1.68; 95% CI, 1.16–2.42; P=0.006) and remained independently prognostic for endometrioid histology and FIGO stage I cases. Vimentin loss was an independent predictor of lymph node metastases (HR, 1.83; 95% CI, 1.13–2.95; P=0.014). The authors concluded that vimentin expression in preoperative biopsies was a robust marker of poor prognosis, adding that incorporating vimentin testing into clinical workflows could enhance preoperative risk stratification and guide personalized treatment decisions for patients with EC.